Experimental combo aims to supercharge cancer immunotherapy
NCT ID NCT03236935
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The goal was to find a safe dose, not to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
L-NMMA and pembrolizumab (Keytruda)
What this could lead to
If successful, this could point toward a new combination treatment that helps the immune system fight several types of cancer more effectively.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, focused on safety. It is too small to prove whether the combination works, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States